

Freedom of Information Act 2000 - Request Reference FoI/22/160
Multiple Myeloma

Information Requested:

- 1. Could you please tell me how many patients have you treated in the last 3 months for Multiple Myeloma?**

160 active Chemocare myeloma patients since January 14 2022 (until April 14 2022) This number is 137 if you exclude BMT only patients in this time.

- 2. Further, how many have received the following treatments?**

Treatment	Patients in last 3 months
Bortezomib [Velcade] and Dexamethasone	19
Bortezomib [Velcade], Thalidomide and Dexamethasone [known as VTD]	10
Bortezomib [Velcade], Cyclophosphamide/Melphalan and Dexamethasone/Prednisolone [known as VCD or VMP]	8
Lenalidomide [Revlimid] monotherapy	0
Lenalidomide [Revlimid] and Dexamethasone	46
Lenalidomide [Revlimid], Bortezomib [Velcade] and Dexamethasone	0
Lenalidomide [Revlimid], Melphalan and Prednisolone	0
Thalidomide, Cyclophosphamide/Melphalan, and Dexamethasone/Prednisolone [known as MPT or CTD]	0
Bortezomib [Velcade] monotherapy	0
Carfilzomib [Kyprolis] and Dexamethasone	0
Carfilzomib [Kyprolis], Lenalidomide [Revlimid], and Dexamethasone [known as KRd]	3
Daratumumab [Darzalex], Velcade [Bortezomib] and Dexamethasone [known as DVD]	25 (Inc DREAMM Trial)
Daratumumab [Darzalex], Velcade [Bortezomib], Thalidomide and Dexamethasone [known as Dara-VTd]	3
Daratumumab [Darzalex], Lenalidomide [Revlimid] and Dexamethasone	0
Daratumumab [Darzalex], Pomalidomide [Imnovid] and Dexamethasone (DaraPd)	0
Daratumumab [Darzalex] monotherapy	17
Isatuximab [Sarclisa], Pomalidomide [Imnovid] and Dexamethasone [known as IsaPd]	4
Isatuximab [Sarclisa], Carfilzomib [Kyprolis] and Dexamethasone [known as IsaKd]	0
Ixazomib [Ninlaro], Lenalidomide [Revlimid] and Dexamethasone [known as IRd]	15
Pomalidomide [Imnovid] and Dexamethasone	8
Panobinostat [Farydak], Bortezomib [Velcade] and Dexamethasone	0
Any other systemic anti-cancer treatment	38 (10 excluding BMT)